Trial Profile
A Phase II Study of AZD2171 in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cediranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 13 Nov 2008 Planned end date changed from 1 Aug 2007 to 1 Oct 2008 according to ClinicalTrials.gov.
- 13 Nov 2008 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.
- 07 Sep 2007 Status changed from recruiting to in progress.